| Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells A Facciabene, X Peng, IS Hagemann, K Balint, A Barchetti, LP Wang, ... Nature 475 (7355), 226-230, 2011 | 1347 | 2011 |
| T-regulatory cells: key players in tumor immune escape and angiogenesis A Facciabene, GT Motz, G Coukos Cancer research 72 (9), 2162-2171, 2012 | 893 | 2012 |
| Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy RJ Buckanovich, A Facciabene, S Kim, F Benencia, D Sasaroli, K Balint, ... Nature medicine 14 (1), 28-36, 2008 | 598 | 2008 |
| Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors D Dangaj, M Bruand, AJ Grimm, C Ronet, D Barras, PA Duttagupta, ... Cancer cell 35 (6), 885-900. e10, 2019 | 546 | 2019 |
| Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response M Uribe-Herranz, S Rafail, S Beghi, L Gil-de-Gómez, I Verginadis, ... The Journal of clinical investigation 130 (1), 466-479, 2020 | 196 | 2020 |
| Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy M Smith, A Dai, G Ghilardi, KV Amelsberg, SM Devlin, R Pajarillo, ... Nature medicine 28 (4), 713-723, 2022 | 151 | 2022 |
| Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer SF Adams, DA Levine, MG Cadungog, R Hammond, A Facciabene, ... Cancer 115 (13), 2891-2902, 2009 | 148 | 2009 |
| Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12 M Uribe-Herranz, K Bittinger, S Rafail, S Guedan, S Pierini, C Tanes, ... JCI insight 3 (4), 2018 | 136 | 2018 |
| Baculovirus vectors elicit antigen-specific immune responses in mice A Facciabene, L Aurisicchio, N La Monica Journal of virology 78 (16), 8663-8672, 2004 | 136 | 2004 |
| Targeting mitochondria in cancer: current concepts and immunotherapy approaches S Pustylnikov, F Costabile, S Beghi, A Facciabene Translational Research 202, 35-51, 2018 | 124 | 2018 |
| Endothelin B receptor, a new target in cancer immune therapy LE Kandalaft, A Facciabene, RJ Buckanovich, G Coukos Clinical cancer research 15 (14), 4521-4528, 2009 | 116 | 2009 |
| The dark side of tumor-associated endothelial cells F De Sanctis, S Ugel, J Facciponte, A Facciabene Seminars in Immunology 35, 35-47, 2018 | 104 | 2018 |
| Association of antibiotic exposure with survival and toxicity in patients with melanoma receiving immunotherapy JJ Mohiuddin, B Chu, A Facciabene, K Poirier, X Wang, A Doucette, ... JNCI: Journal of the National Cancer Institute 113 (2), 162-170, 2021 | 95 | 2021 |
| Efficient induction of T‐cell responses to carcinoembryonic antigen by a heterologous prime‐boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA C Mennuni, F Calvaruso, A Facciabene, L Aurisicchio, M Storto, ... International journal of cancer 117 (3), 444-455, 2005 | 78 | 2005 |
| Tumor endothelial marker 1–specific DNA vaccination targets tumor vasculature JG Facciponte, S Ugel, F De Sanctis, C Li, L Wang, G Nair, S Sehgal, ... The Journal of clinical investigation 124 (4), 2014 | 74 | 2014 |
| Maternal dendrimer-based therapy for inflammation-induced preterm birth and perinatal brain injury J Lei, JM Rosenzweig, MK Mishra, W Alshehri, F Brancusi, M McLane, ... Scientific reports 7 (1), 6106, 2017 | 63 | 2017 |
| Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy I Alagkiozidis, A Facciabene, M Tsiatas, C Carpenito, F Benencia, ... Journal of translational medicine 9, 1-12, 2011 | 59 | 2011 |
| Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy A Facciabene, F De Sanctis, S Pierini, ES Reis, K Balint, J Facciponte, ... Oncoimmunology 6 (9), e1326442, 2017 | 55 | 2017 |
| DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection A Facciabene, L Aurisicchio, L Elia, F Palombo, C Mennuni, G Ciliberto, ... Human gene therapy 17 (1), 81-92, 2006 | 55 | 2006 |
| The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade LE Kandalaft, N Singh, JB Liao, A Facciabene, JS Berek, DJ Powell Jr, ... Gynecologic oncology 116 (2), 222-233, 2010 | 52 | 2010 |
